MindRank Publicizes U.S. FDA Clearance of IND Software for MDR-001, a Novel GLP-1 Receptor Agonist for the Therapy of Kind 2 Diabetes and Weight problems

MindRank Publicizes U.S. FDA Clearance of IND Software for MDR-001, a Novel GLP-1 Receptor Agonist for the Therapy of Kind 2 Diabetes and Weight problems

SHANGHAI and HANGZHOU, China, Dec. 26, 2022 /PRNewswire/ — MindRank, a synthetic intelligence (AI)-empowered drug discovery firm, broadcasts at this time that the U.S. Meals and Drug Administration (FDA) has cleared the corporate’s Investigational New Drug (IND) utility for MDR-001, an oral small-molecule glucagon-like peptide 1 receptor agonist (GLP-1 RA), for the remedy of weight problems and kind 2 diabetes mellitus (T2DM), respectively. MindRank expects to provoke a Part I security research within the first quarter of 2023.

Empowered by Mindrank’s proprietary AI drug discovery platform, Molecule Professional™, it simply took the corporate 19 months to acquire the IND approval because the MDR-001 program was initiated. With fewer than 100 chemical compounds synthesized and examined, the preclinical candidate was found.

“By facilitating novel small molecule drug design with desired drug-like properties, we imagine our AI platform can considerably enhance the pre-clinical R&D effectivity. The FDA IND approval of MDR-001 is a strong validation for the potential of our AI platform.” commented Zhangming Niu, CEO of MindRank. This heralds the transition of MindRank from a discovery-stage to a clinical-stage AI-empowered biotechnology firm.

About MDR-001

MDR-001 is a novel, orally bioavailable small-molecule GLP-1 RA found utilizing MindRank’s proprietary AI platform, Molecule Professional™. Within the complete preclinical research, MDR-001 has demonstrated wonderful practical efficiency and selectivity, with favorable ADME properties and oral bioavailability, in addition to fascinating pharmacokinetics and tolerability. MDR-001’s superior preclinical efficacy and security profiles point out its best-in-class potential for Weight problems and T2DM indications with massive unmet medical wants.

About MindRank

MindRank is a synthetic intelligence (AI)-empowered drug discovery firm. By leveraging its proprietary AI platform, Molecule Professional, the corporate goals to considerably speed up the drug discovery course of and ship small molecule medication with fascinating efficacy and security profiles.

To be taught extra, go to www.mindrank.ai .

SOURCE MindRank

MindRank Publicizes U.S. FDA Clearance of IND Software for MDR-001, a Novel GLP-1 Receptor Agonist for the Therapy of Kind 2 Diabetes and Weight problems